BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
Jiaji G. Chen(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Zachary R. Hunter(Harvard University), Christopher J. Patterson(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), Maria Luisa Guerrera(Harvard University), Manit Munshi(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Sara J. Buhrlage(Harvard University), Patricia Severns(Harvard University), Steven P. Treon(Dana-Farber Cancer Institute), Toni Dubeau(Shaanxi Research Association for Women and Family), Jinhua Wang(Harvard University), Xia Liu(Northwestern University), Nathanael S. Gray(Stanford University), Lian Xu(Huazhong Agricultural University), Jorge J. Castillo(Dana-Farber Cancer Institute)
Cited by 84
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k